Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The first meningococcal serogroup C (MenC) conjugate vaccine was licensed in 1999 and introduced in the United Kingdom. Countries that have implemented the MenC vaccine since then in their national immunisation programmes use different schedules. Nevertheless, all involved countries seem to experience substantial declines in the incidence of MenC disease. DISCUSSION: Since 2001, the MenC conjugate vaccine has been implemented in the Netherlands by offering a single dose to all children aged 14 months. Prior to the introduction of the vaccine into the national immunisation programme, a catch-up vaccination campaign was initiated in which a single dose of the MenC conjugate vaccine was offered to all children aged from 14 months up to and including 18 years. Since then, there has been no report of any case of MenC disease among immunocompetent vaccinees. Administration of a single dose of MenC conjugate vaccine after infancy could be beneficial considering the already complex immunisation schedules with large numbers of vaccinations in the first year of life. The present paper deals with the advantages and critical aspects of a single dose of the MenC conjugate vaccine. SUMMARY: A single dose of MenC conjugate vaccine at the age of 14 months in combination with a catch up vaccine campaign appeared to be a successful strategy to prevent MenC disease in the Netherlands, thereby confirming that a single dose of the vaccine could sufficiently protect against disease. Nevertheless, this approach can only be justified in countries with a relatively low incidence of serogroup C meningococcal disease in the first year of life. Furthermore, a good surveillance programme is recommended for timely detection of vaccine breakthroughs and outbreaks among non-vaccinees, since long-term protection after a single dose in the second year of life cannot currently be guaranteed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
Maiden, M. C. J., Ibarz-Pavón, A. B., Urwin, R., Gray, S. J., Andrews, N. J., Clarke, S. C., Walker, A. M., Evans, M. R., Kroll, J. S., Neal, K. R., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/527401 · Cited by 442
Cited by
Bijlsma, M. W., Brouwer, M. C., Kasanmoentalib, E. S., Kloek, A. T., Lucas, M. J., Tanck, M. W., van der Ende, A., & van de Beek, D. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00430-2 · Cited by 412
Effect of vaccines on bacterial meningitis worldwide
McIntyre, P. B., O'Brien, K. L., Greenwood, B., & van de Beek, D. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61187-8 · Cited by 326
Pelton, S. I. (2016) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2016.04.012 · Cited by 199
Pace, D., Khatami, A., McKenna, J., Campbell, D., Attard-Montalto, S., Birks, J., Voysey, M., White, C., Finn, A., Macloed, E., et al. (2015) · BMJ · doi:10.1136/bmj.h1554 · Cited by 28
Metadata
- Authors
- Kaaijk, P., van der Ende, A., Berbers, G., van den Dobbelsteen, G. P., & Rots, N. Y.
- Venue
- BMC Infectious Diseases
- Published
- 2012-02-08
- Volume
- 12
- Issue
- 1
- Pages
- 35-35
- ISSN
- 1471-2334 (ISSN-L)
- OpenAlex
- W2043799760
- Cited by
- 42
- References
- 1
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands. https://app.cochat.ai/papers/10.1186/1471-2334-12-35
- The paper
- Kaaijk, P., van der Ende, A., Berbers, G., van den Dobbelsteen, G. P., & Rots, N. Y. (2012). Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands. BMC Infectious Diseases. https://doi.org/10.1186/1471-2334-12-35
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.